Table 2 Baseline patient, tumor, and treatment characteristics for all patients (n = 115) and broken down by patients did or did not experience SL
Characteristic | Total (N = 115) | SL (N = 63) | No SL (N = 52) | P value |
|---|---|---|---|---|
Age at diagnosis, years, Median (IQR) | 63.00 (59.00–67.00) | 63.00 (60.00–67.00) | 62.50 (55.50–67.00) | 0.362 |
Sex | ||||
Male | 107 (92.2%) | 59 (51.3%) | 48 (41.7%) | |
Female | 8 (7.0%) | 4 (3.5%) | 4 (3.5%) | 0.778 |
ECOG performance status | ||||
0–1 | 84 (73.0%) | 44 (38.3%) | 40 (34.8%) | |
2 | 31 (27.0%) | 19 (16.5%) | 12 (10.4%) | 0.394 |
Smoking pack-years | ||||
≥ 10 | 80 | 45 | 35 | |
0–10 | 4 | 3 | 1 | |
0 | 24 | 12 | 12 | |
Unkown | 7 | 3 | 4 | 0.717 |
Histology | ||||
Squamous carcinoma | 78 (67.8%) | 49 (42.2%) | 35 (30.4%) | |
Adenocarcinoma | 34 (29.6%) | 19 (16.5%) | 15 (13.0%) | |
Others | 3 (2.6%) | 1 (0.9%) | 2 (1.7%) | 0.683 |
cT stage (AJCC 8th ed) | ||||
T1 | 14 (12.2%) | 8 (7.0%) | 6 (5.2%) | |
T2 | 31 (26.7%) | 20 (17.2%) | 11 (9.57%) | |
T3 | 27 (23.5%) | 12 (10.4%) | 15 (13.0%) | |
T4 | 43 (37.4%) | 23 (20.0%) | 20 (17.4%) | 0.492 |
cN stage | ||||
N1 | 6 (5.2%) | 2 (1.7%) | 4 (3.5%) | |
N2 | 73 (63.5%) | 39 (33.9%) | 34 (29.6%) | |
N3 | 36 (31.3%) | 22 (19.1%) | 14 (12.2%) | 0.417 |
Stage | ||||
IIIA | 33 (28.7%) | 18 (15.7%) | 15 (13.0%) | |
IIIB | 61 (53.0%) | 33 (28.7%) | 28 (24.3%) | |
IIIC | 21 (18.3%) | 12 (10.4%) | 9 (7.8%) | 0.971 |
TLCs, cells/μL (median, IQR) | ||||
Baseline | 1600 (1400–2000) | 1600 (1300–1900) | 1800 (1400–2200) | 0.037 |
Pre-RT | 1800 (1400–2100) | 1600 (1280–1900) | 1965 (1700–2252) | < 0.001 |
TLC nadir during the course of RT | 500 (380–700) | 390 (300–470) | 700 (600–830) | < 0.001 |
1 month after RT | 915 (700–1100) | 800 (598–1100) | 995 (882–1232) | 0.004 |
2 month after RT | 900 (700–1100) | 740 (600–982) | 1000 (810–1195) | < 0.001 |
Tumor volume, cm3 (median, IQR) | ||||
GTV | 56.85 (32.47–129.35) | 87.69 (45.58–144.92) | 43.40 (21.84–95.52) | 0.006 |
PTV | 146.03 (74.20–247.39) | 160.95 (80.69–258.92) | 124.82 (71.13–224.05) | 0.192 |
EQD2 (Gy or Gy[RBE]) (median, IQR) | 64.00 (60.00–65.00) | 62.87 (60.00–65.10) | 65.00 (60.00–65.00) | 0.755 |
BED (Gy) | 76.80 (72.00–78.00) | 75.44 (72.00–78.13) | 78 (72–78) | 0.768 |
Fractions, number (median, IQR) | 25 (20–30) | 25 (25–30) | 25 (20–30) | 0.141 |
OTT, days (median, IQR) | 39 (31–43) | 39 (33–43) | 35 (29–43) | 0.281 |
Key mean normal tissue doses, cGy (median, IQR) | ||||
Mean lung dose | 1275 (1078–1454) | 1354.90 (1146.00–1480.00) | 1165 (990–1386) | 0.007 |
Mean heart dose | 601 (420–1261.50) | 886 (439.00–1502.25) | 518 (384–936.90) | 0.041 |
Radiation technique | ||||
3D conformal | 28 (24.3%) | 16 (13.9%) | 12 (10.4%) | |
Intensity modulated | 37 (32.2%) | 19 (16.5%) | 18 (15.7%) | |
Helical Tomotherapy | 50 (43.5%) | 28 (24.3%) | 22 (19.1%) | 0.874 |
Concurrent chemoradiation (sequential) | ||||
Yes | 31 (27.0%) | 15 (12.9%) | 16 (13.9%) | |
No | 84 (73.0%) | 48 (41.7%) | 36 (31.3%) | 0.403 |
Induction chemotherapy | ||||
Yes | 91 (79.1%) | 54 (47.0%) | 37 (32.2%) | |
No | 24 (20.9%) | 9 (7.8%) | 15 (13.0%) | 0.056 |
Adjuvant chemotherapy | ||||
Yes | 61 (53.0%) | 31 (27.0%) | 30 (26.1%) | |
No | 54 (47.0%) | 32 (27.8%) | 22 (19.1%) | 0.364 |